We evaluated IPH6501, a clinical-stage, tetraspecific NK cell engager (NKCE) armed with a non-alpha IL-2 variant (IL-2v), which targets CD20 and was developed for treating B cell non-Hodgkin lymphoma (B-NHL)...In vivo studies in nonhuman primates and tumor mouse models further validated its efficacy and revealed that CD20-NKCE-IL2v induces peripheral NK cell homing at the tumor site. CD20-NKCE-IL2v emerges as a potential alternative in the treatment landscape of B-NHL.
Despite several generations of CD20-targeting drugs including rituximab, ofatumumab, and obinutuzumab, and more recent approvals of new CD20-targeting agents, innovative strategies are still needed for B-NHL patients who relapse or are refractory (R/R) after multiple lines of treatment. Our preclinical data showed that IPH6501, a CD20-targeting tetraspecific antibody-based NK cell engager therapeutic, could be a powerful first-in-class new asset to harness the anti-tumor functions of NK cells in CD20 +B-cell malignancies. IPH6501 is expected to enter FIH clinical study in 2023. 1.
over 1 year ago
IO biomarker
|
IL2RA (Interleukin 2 receptor, alpha) • FCGR3A (Fc Fragment Of IgG Receptor IIIa)